Non-small cell lung cancer PDL1 >50%-should we go single or combo?

Waleed Kian, Laila C. Roisman, Dina Levitas, Nadav Wallach, Adam Abo-Sharb, Aharon Y. Cohen, Alexander Yakobson, Nir Peled, Yulia Dudnik

    Research output: Contribution to journalReview articlepeer-review

    2 Scopus citations

    Fingerprint

    Dive into the research topics of 'Non-small cell lung cancer PDL1 >50%-should we go single or combo?'. Together they form a unique fingerprint.

    Keyphrases

    Medicine and Dentistry

    Pharmacology, Toxicology and Pharmaceutical Science

    Biochemistry, Genetics and Molecular Biology

    Neuroscience